Ocular Therapeutix, Inc (OCUL) stock
OCULNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 9, 2026Score 3/309% above fair value
$5.94−0.08 (-1.33%)
Close on Nov 18, 2026Market cap $1.30BP/E –Yield –
Ocular Therapeutix free cash flow
Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.
Ocular Therapeutix's free cash flow for the twelve months ending Jun 30, 2026 was -$255.10M. For fiscal 2025 it was -$216.89M. The highest annual figure on record is -$12.79M in fiscal 2012.
Annual free cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$216.89M | – |
| FY2024 | Dec 31, 2024 | -$135.97M | – |
| FY2023 | Dec 31, 2023 | -$76.32M | – |
| FY2022 | Dec 31, 2022 | -$63.32M | – |
| FY2021 | Dec 31, 2021 | -$66.74M | – |
| FY2020 | Dec 31, 2020 | -$54.40M | – |
| FY2019 | Dec 31, 2019 | -$79.82M | – |
| FY2018 | Dec 31, 2018 | -$51.12M | – |
| FY2017 | Dec 31, 2017 | -$58.73M | – |
| FY2016 | Dec 31, 2016 | -$35.92M | – |
| FY2015 | Dec 31, 2015 | -$35.52M | – |
| FY2014 | Dec 31, 2014 | -$21.76M | – |
| FY2013 | Dec 31, 2013 | -$13.03M | – |
| FY2012 | Dec 31, 2012 | -$12.79M | – |
Quarterly free cash flow
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$70.64M | – |
| Q1 FY2026 | Mar 31, 2026 | -$70.66M | – |
| Q4 FY2025 | Dec 31, 2025 | -$57.09M | – |
| Q3 FY2025 | Sep 30, 2025 | -$56.72M | – |
| Q2 FY2025 | Jun 30, 2025 | -$56.48M | – |
| Q1 FY2025 | Mar 31, 2025 | -$46.60M | – |
| Q4 FY2024 | Dec 31, 2024 | -$39.63M | – |
| Q3 FY2024 | Sep 30, 2024 | -$36.65M | – |
| Q2 FY2024 | Jun 30, 2024 | -$25.54M | – |
| Q1 FY2024 | Mar 31, 2024 | -$34.14M | – |
| Q4 FY2023 | Dec 31, 2023 | -$22.91M | – |
| Q3 FY2023 | Sep 30, 2023 | -$7.99M | – |
| Q2 FY2023 | Jun 30, 2023 | -$22.07M | – |
| Q1 FY2023 | Mar 31, 2023 | -$23.35M | – |
| Q4 FY2022 | Dec 31, 2022 | -$19.11M | – |
| Q3 FY2022 | Sep 30, 2022 | -$13.96M | – |
| Q2 FY2022 | Jun 30, 2022 | -$11.37M | – |
| Q1 FY2022 | Mar 31, 2022 | -$18.88M | – |
| Q4 FY2021 | Dec 31, 2021 | -$15.78M | – |
| Q3 FY2021 | Sep 30, 2021 | -$13.26M | – |
| Q2 FY2021 | Jun 30, 2021 | -$20.19M | – |
| Q1 FY2021 | Mar 31, 2021 | -$17.52M | – |
| Q4 FY2020 | Dec 31, 2020 | -$6.50M | – |
| Q3 FY2020 | Sep 30, 2020 | -$13.87M | – |
| Q2 FY2020 | Jun 30, 2020 | -$14.92M | – |
| Q1 FY2020 | Mar 31, 2020 | -$19.10M | – |
| Q4 FY2019 | Dec 31, 2019 | -$20.07M | – |
| Q3 FY2019 | Sep 30, 2019 | -$19.96M | – |
| Q2 FY2019 | Jun 30, 2019 | -$19.67M | – |
| Q1 FY2019 | Mar 31, 2019 | -$20.11M | – |
| Q4 FY2018 | Dec 31, 2018 | -$14.13M | – |
| Q3 FY2018 | Sep 30, 2018 | -$11.35M | – |
| Q2 FY2018 | Jun 30, 2018 | -$12.79M | – |
| Q1 FY2018 | Mar 31, 2018 | -$12.85M | – |
| Q4 FY2017 | Dec 31, 2017 | -$10.95M | – |
| Q3 FY2017 | Sep 30, 2017 | -$16.42M | – |
| Q2 FY2017 | Jun 30, 2017 | -$15.13M | – |
| Q1 FY2017 | Mar 31, 2017 | -$16.23M | – |
| Q4 FY2016 | Dec 31, 2016 | -$8.29M | – |
| Q3 FY2016 | Sep 30, 2016 | -$8.20M | – |
See a number that looks wrong?